The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | CAR T-cell therapy and BiTEs for myeloma
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, outlines results of the use of teclistamab, a BCMA x CD3 bispecific antibody in relapsed/refractory multiple myeloma (MM) patients, in addition to updates from KarMMa and CARTITUDE-1, evaluating the efficacy and safety of CAR T-cell therapies in MM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
